Introduction: Who Should Seek Diagnostic Testing

Congenital myopathy is a rare genetic muscle disorder that typically becomes noticeable at birth or during the first months and years of life. Parents and healthcare providers should consider diagnostic testing when a baby or young child shows certain warning signs that suggest muscle weakness or poor muscle tone. These conditions affect approximately 6 in every 100,000 live births worldwide, making early recognition important for appropriate care.^[1][8]

The most common early sign that prompts families to seek medical evaluation is when an infant appears unusually “floppy” or lacks the muscle tone expected for their age. This condition, called hypotonia, means the baby’s muscles feel softer and less resistant to movement than they should. Parents might notice their infant has difficulty holding their head up, seems to lie limply when picked up, or feels like a “rag doll” in their arms. These observations often lead to the first medical consultation.^[1][2]

Diagnostic evaluation becomes particularly urgent when breathing or feeding difficulties appear. Some babies with congenital myopathy struggle to breathe properly because the muscles that control breathing are weak. They may breathe rapidly, use their neck and chest muscles visibly when breathing, or have episodes where breathing becomes labored. Similarly, feeding problems such as difficulty sucking, swallowing, or coordinating breathing while eating can signal that diagnostic testing is needed. These symptoms require prompt medical attention because they can affect a child’s growth and overall health.^[1][7]

Delayed developmental milestones also warrant diagnostic investigation. When children are slower than expected to reach important movement goals—such as rolling over, sitting up, crawling, or walking—muscle weakness may be the underlying cause. Some children with milder forms of congenital myopathy may not show obvious problems until they are toddlers or even older, when parents notice they tire easily, have trouble climbing stairs, or struggle with activities their peers manage without difficulty.^[1][17]

Physical signs like skeletal problems may also prompt diagnostic testing. These can include a curved spine (called scoliosis), an elongated facial structure sometimes described as “myopathic facies,” drooping eyelids, difficulty moving the eyes in different directions, or feet that are positioned abnormally. When these features appear alongside muscle weakness, they provide important clues about the presence of a congenital myopathy.^[1][17]

Family history also plays a role in determining who should undergo diagnostic testing. Because congenital myopathies are genetic conditions passed from parents to children through changes in specific genes, a family history of muscle disorders or unexplained infant deaths may indicate increased risk. In such cases, doctors may recommend earlier or more comprehensive testing, even if symptoms are subtle.^[1][17]

Classic Diagnostic Methods

Diagnosing congenital myopathy requires multiple steps because these conditions can have overlapping symptoms with other neuromuscular disorders. The diagnostic process begins with a thorough medical history and physical examination. During the initial consultation, the doctor will ask detailed questions about when symptoms first appeared, how they have progressed, and whether any family members have similar conditions. They will carefully observe the child’s muscle tone, strength, reflexes, and movement patterns.^[1][8]

The physical examination focuses on identifying patterns of muscle weakness. Doctors typically find that the muscles closest to the center of the body—particularly those around the hips, shoulders, and neck—are most affected in congenital myopathy. The muscles of the hands and feet are usually less involved, though there are exceptions depending on the specific type. The healthcare provider will also examine facial muscles, checking for drooping eyelids, reduced facial expression, or difficulty moving the eyes. These observations help distinguish congenital myopathy from other conditions that cause muscle weakness.^[17][5]

Blood testing represents one of the earliest laboratory tests performed during the diagnostic process. A simple blood sample can measure levels of creatine kinase, an enzyme that leaks from damaged muscle cells into the bloodstream. In many muscle diseases, creatine kinase levels are very high, but in most congenital myopathies, these levels are either normal or only mildly elevated. This characteristic helps doctors narrow down the possible diagnoses. However, a normal creatine kinase level does not rule out congenital myopathy, so additional testing is usually needed.^[8][17]

Electromyography, often abbreviated as EMG, is another diagnostic tool used to evaluate muscle and nerve function. During this test, small needles are inserted into various muscles to measure their electrical activity. The patterns recorded can indicate whether the problem lies in the muscles themselves, the nerves that control them, or the connection between nerves and muscles. In congenital myopathies, the EMG typically shows patterns consistent with muscle disease, though the results can sometimes be non-specific or even normal, which is why EMG alone cannot provide a definitive diagnosis.^[7][8]

Muscle biopsy has traditionally been one of the most important diagnostic procedures for congenital myopathy. During a muscle biopsy, a small piece of muscle tissue is surgically removed and examined under a microscope. Different types of congenital myopathy show distinctive features when muscle tissue is viewed this way. For example, in central core disease, the center of muscle fibers lacks certain enzymes that are visible with special staining techniques. In nemaline myopathy, small rod-shaped structures appear within the muscle fibers. In centronuclear myopathy, the nuclei of muscle cells are positioned in the center rather than at the edges where they normally belong.^[8][5]

The muscle biopsy procedure typically involves removing tissue from a muscle in the thigh or upper arm. The sample is then processed using various staining methods and examined under both light and electron microscopes. Different staining techniques highlight different cellular structures, helping pathologists identify the characteristic abnormalities associated with each type of congenital myopathy. While muscle biopsy has been valuable historically, it has limitations. Sometimes the biopsy sample comes from an area of muscle that doesn’t show the typical changes, or the changes are too subtle or non-specific to provide a clear diagnosis.^[8][6]

Genetic testing has become increasingly important in diagnosing congenital myopathy and, in many cases, has reduced the need for muscle biopsy. This testing looks for mutations in the specific genes known to cause different types of congenital myopathy. A blood sample is analyzed to read the genetic code and identify any changes or “misspellings” in genes that control muscle function. Genetic testing can identify mutations through sequencing, which examines the detailed genetic code letter by letter, or through deletion and duplication testing, which looks for larger sections of genetic material that are missing or extra.^[8][15]

More than 30 different genes have been associated with various types of congenital myopathy. For instance, mutations in the RYR1 gene commonly cause central core disease and some forms of multicore disease. Mutations in genes like NEB, ACTA1, and TPM2 can cause nemaline myopathy. Mutations in the MTM1 gene cause myotubular myopathy, while mutations in DNM2, BIN1, or RYR1 can cause centronuclear myopathy. Identifying the specific genetic mutation not only confirms the diagnosis but also provides information about inheritance patterns and helps predict how the condition might progress.^[1][6]

Imaging studies, particularly magnetic resonance imaging (MRI) of the muscles, have emerged as useful diagnostic tools. MRI can show patterns of muscle involvement without requiring invasive procedures. Different types of congenital myopathy affect specific muscle groups in characteristic ways, and MRI can reveal which muscles are replaced by fat or show other abnormal changes. This information helps narrow down the diagnosis and can guide decisions about which genetic tests to order or whether muscle biopsy is necessary.^[5][13]

Respiratory function testing helps assess how well breathing muscles are working. This is particularly important because breathing problems are common in congenital myopathies and can significantly affect health and quality of life. Simple tests measure how much air the lungs can hold and how forcefully air can be exhaled. More detailed testing might include overnight monitoring of breathing patterns and oxygen levels during sleep, because breathing difficulties often worsen at night when muscles naturally relax. Morning headaches, snoring, or excessive daytime sleepiness can indicate that nighttime breathing problems exist.^[9][13]

Swallowing studies may be performed if feeding difficulties are present. These tests, often called swallow evaluations, involve observing the child eating and drinking, sometimes using special imaging techniques to watch how food and liquid move from the mouth to the stomach. This helps identify whether muscle weakness affects swallowing safety and whether special feeding strategies or interventions are needed to prevent food or liquid from entering the lungs.^[13][15]

Diagnostics for Clinical Trial Qualification

When patients with congenital myopathy are being considered for enrollment in clinical trials, additional diagnostic tests and assessments are typically required beyond those used for routine clinical diagnosis. Clinical trials testing new treatments need to ensure that participants truly have the condition being studied and that they can be safely monitored throughout the trial. These requirements help researchers accurately measure whether experimental treatments are working and ensure participant safety.^[13][6]

Confirmed genetic diagnosis is usually essential for clinical trial participation. Trials testing treatments aimed at specific genetic forms of congenital myopathy require documented proof that participants carry mutations in the relevant gene. For example, a trial testing a treatment for myotubular myopathy caused by MTM1 gene mutations would require genetic testing results showing mutations in that specific gene. This genetic confirmation ensures that the treatment being tested is appropriate for the participant’s particular form of congenital myopathy.^[6][13]

Baseline muscle function assessments are standard requirements for clinical trial enrollment. These measurements establish the participant’s starting level of muscle strength and function so researchers can determine whether the experimental treatment causes improvement, stabilization, or continued decline. Common assessments include standardized tests of muscle strength in different body parts, timed tests of functional abilities like standing from sitting or walking a specific distance, and questionnaires about daily activities. These same assessments are then repeated at regular intervals throughout the trial to track changes.^[13]

Comprehensive respiratory function testing is typically required for clinical trial qualification, especially in congenital myopathies where breathing muscle weakness is common. Trials need detailed information about lung capacity, breathing muscle strength, and whether participants require breathing support devices. Tests measure forced vital capacity (the maximum amount of air that can be forcefully exhaled), peak cough flow (how forcefully someone can cough), and overnight oxygen saturation levels. These measurements help establish eligibility criteria and serve as important outcome measures to evaluate treatment effectiveness.^[13]

Cardiac evaluation is often required before clinical trial enrollment because some congenital myopathies can affect heart muscle or because experimental treatments might have cardiac effects. Standard tests include electrocardiogram (ECG), which records the heart’s electrical activity, and echocardiogram (ultrasound of the heart), which evaluates heart structure and function. These baseline cardiac assessments ensure it is safe for participants to receive the experimental treatment and provide comparison points for monitoring heart health throughout the trial.^[13]

Laboratory tests form another important component of clinical trial screening. Blood tests typically include complete blood counts to check blood cell levels, liver function tests to ensure the liver is working properly, kidney function tests, and sometimes immune system assessments. These tests help identify any pre-existing health issues that might make trial participation unsafe or that might complicate interpretation of treatment effects. Many experimental treatments require normal or near-normal organ function for safe participation.^[13]

Imaging studies, particularly MRI of affected muscles, may be required as part of clinical trial enrollment. Advanced MRI techniques can measure the amount of muscle that has been replaced by fat and can detect inflammation or other changes in muscle tissue. These imaging studies provide objective measures of disease severity and can serve as outcome measures to evaluate whether experimental treatments slow disease progression or improve muscle health.^[13]

Nutritional assessment is sometimes included in clinical trial evaluations because proper nutrition affects muscle health and overall wellbeing. Assessments may include measurements of weight, height, and body composition, along with evaluation of whether participants can eat safely by mouth or require feeding tubes. Some trials have specific nutritional requirements for eligibility, and nutritional status is often monitored throughout the trial as both a safety measure and a potential outcome measure.^[13][15]

Quality of life questionnaires are increasingly used in clinical trials to understand how congenital myopathy affects daily living from the patient and family perspective. These standardized questionnaires ask about physical abilities, emotional wellbeing, social interactions, and overall life satisfaction. They help researchers understand whether experimental treatments improve not just measurable physical parameters but also participants’ actual experiences of living with their condition.^[13]

Age requirements and disease severity criteria vary among clinical trials. Some trials specifically seek participants with more severe forms of congenital myopathy who might benefit most from intervention, while others may focus on milder forms or specific age groups. Trials of gene therapy approaches often require that participants have a confirmed genetic mutation that the therapy is designed to correct. Additionally, some trials may exclude participants who use certain medications or who have received other experimental treatments within a specific timeframe.^[6][11]

The diagnostic procedures required for clinical trial qualification are generally more extensive and standardized than those needed for routine clinical care. While this may seem burdensome, these rigorous assessments serve important purposes: they ensure participant safety, provide accurate baseline measurements, enable meaningful evaluation of treatment effects, and help advance scientific understanding of these rare conditions. Families interested in clinical trial participation should discuss with their healthcare team which trials might be appropriate and what diagnostic assessments would be needed.^[13]